Tcr2 Therapeutics - TCRR STOCK NEWS

TCR² Therapeutics (Nasdaq: TCRR) has appointed Eric Sullivan as Chief Financial Officer, effective immediately. Sullivan, with nearly 20 years of experience in biotechnology finance and operations, previously held leadership positions at Triplet Therapeutics and bluebird bio. His role will focus on financial management, capital market strategy, and investor relations as TCR² approaches critical milestones for its clinical programs, gavo-cel and TC-510. The leadership change is expected to enhance the company's capabilities to maximize value during its next growth phase.

TCR2 Therapeutics Inc. (Nasdaq: TCRR) announced the grant of inducement stock options totaling 19,800 shares to three new non-executive employees on May 31, 2022. The options have an exercise price of $2.32, matching the market price on the grant date, and will vest over a four-year period. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent to strengthen the company’s pipeline of T cell therapies for solid tumors. TCR2 continues to focus on developing its proprietary TRuC platform for effective cancer treatment.

TCR² Therapeutics (Nasdaq: TCRR) announced participation in two upcoming conferences in June 2022, focusing on its novel T cell therapies for solid tumors.

• Alfonso Quintás-Cardama, Chief Medical Officer, will present at the Jefferies Healthcare Conference on June 8, 2022, at 2:00 PM E.T.
• Garry Menzel, President and CEO, will join a panel at the Truist Securities Life Sciences Symposia-cel on June 27, 2022, at 12:00 PM E.T.

Live webcasts will be available on the Investors page of the company’s website, with archived replays for 30 days.

TCR² Therapeutics Inc. (Nasdaq: TCRR) reported its Q1 2022 financial results and announced significant advancements in its clinical programs. The company launched the Phase 2 expansion of its gavo-cel trial, with updates expected in H2 2022. TCR² also received FDA IND clearance for the TC-510 Phase 1/2 trial, targeting various solid tumors. Financially, TCR² ended Q1 2022 with $232.2 million in cash, reflecting a net loss of $29.1 million. R&D expenses rose to $22.9 million due to increased clinical activities. The company projects a cash burn of $115-125 million for the year.

TCR² Therapeutics Inc. (Nasdaq: TCRR) announced the grant of inducement stock options covering 57,200 shares to four new non-executive employees, approved on April 29, 2022. The options have an exercise price of $2.13, the closing market price on the grant date. They will vest over four years, starting with 25% vesting on the first anniversary of hire and 75% vesting monthly thereafter, contingent on continued employment. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and is part of TCR²'s commitment to attracting talent in its cell therapy development efforts.

TCR² Therapeutics Inc. (Nasdaq: TCRR) announced on April 1, 2022, the grant of inducement stock options for 73,000 shares to 9 new non-executive employees. These options were priced at $2.76, equal to TCR²'s closing stock price on the grant date. The options vest over four years, with 25% vesting on the first anniversary and the remainder monthly. This grant aligns with Nasdaq requirements to incentivize employee retention and performance, as the company focuses on developing novel T cell therapies for solid tumors.

TCR2 Therapeutics Inc. (Nasdaq: TCRR) reported its fourth-quarter financial results for 2021, reflecting a net loss of $27.7 million, an increase from $18.5 million in Q4 2020. The company ended the quarter with $265.6 million in cash, sufficient to fund operations into 2024. Key achievements include submitting a protocol amendment for the gavo-cel Phase 2 trial and an IND for TC-510, enhancing its clinical pipeline. R&D expenses rose to $22.4 million due to increased headcount and restructuring costs. TCR2 projects net cash usage of $115-125 million for 2022.

TCR² Therapeutics Inc. (Nasdaq: TCRR) announced its participation in the AACR Annual Meeting 2022, presenting a poster on April 10, showcasing preclinical data for its allogeneic TRuC-T cell therapy. The data indicates enhanced anti-tumor efficacy and prolonged persistence of these off-the-shelf therapies compared to autologous options. The approach utilizes CRISPR/Cas9 technology to modify T cells, reducing rejection risks while ensuring robust tumor targeting. The poster can be accessed on TCR²'s website after the presentation.

TCR2 Therapeutics Inc. (Nasdaq: TCRR) announced the grant of inducement stock options covering 15,200 shares to three new non-executive employees, approved by the Compensation Committee on February 28, 2022. The options have an exercise price of $2.71, the closing market price on the Grant Date. They will vest over four years, with 25% vesting after one year and the rest in monthly installments. This grant is in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent for their cell therapy developments targeting solid tumors.